Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
The most oversold stocks in the industrials sector are drawing attention as potential opportunities to buy undervalued companies. The latest screen highlights major industrials names with a relative strength index (RSI) near or below 30. TaskUs, Inc. (NASDAQ: TASK) On March 23, Wedbush maintained TaskUs with an Outperform rating and…
Philadelphia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Gossamer securities during the Class Period may, no later than June 1, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. According to the complaint, clinical-stage biopharmaceutical company Gossamer made materially false and misleading statements regarding the design and anticipated outcomes of its Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH). The suit alleges that investors began to learn the truth on February 23, 2026, when Gossamer announced that its Phase 3 PROSERA study failed to meet the primary endpoint of improved six-minute walk distance (6MWD) at Week 24. The Company attributed the results to unexpectedly strong placebo performance at Latin American sites. On this news, Gossamer's stock price fell from $2.13 to $0.42 per share, a decline of over 80% in a single trading day. If you are a Gossamer investor and would like to learn more about this action, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or Caitlin Adorni at cadorni@bergermontague.com.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
